Eli Lilly Stock Slumps as Earnings Guidance Slashed Dramatically

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 42 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 97%

Ireland News News

Ireland Ireland Latest News,Ireland Ireland Headlines

Lilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.

Eli Lilly shares were falling Thursday after the drugmaker significantly slashed its full-year earnings guidance as a result of its deal spree.

Lilly reported earnings of 10 cents a share on revenue of $9.5 billion in the third quarter. Analysts surveyed by FactSet has expected the company to post a loss of 18 cents a share on revenue just shy of $9 billion. What’s disappointing was the outlook. Lilly slashed its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.

The company said the reduced outlook was largely due to in-process research and development charges acquired in the third quarter as a result of Lilly’s deals to buy of DICE Therapeutics, Versanis Bio, and Emergence Therapeutics. Shares in Lilly tumbled 1.7% in premarket trading Thursday, having previously hovered 2% higher before earnings on the back of strong results from peer Novo Nordisk .

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in İE

Ireland Ireland Latest News, Ireland Ireland Headlines